Sermorelin and Semaglutide Together: What Is Known
Sermorelin and Semaglutide taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 11 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | Sermorelin | Semaglutide |
|---|---|---|
| Class | GHRH analog | GLP-1 agonist |
| Also called | — | sema, Ozempic, Wegovy, Rybelsus, Wegovy pill |
| Category | Growth hormone | GLP-1 & metabolic |
| FDA status | Compounded by prescription | FDA approved (Ozempic, Wegovy, Rybelsus) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | approximately 1 weeksubcutaneous · FDA label (Ozempic) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 |
| Human studies we summarised | 6 human (1 randomized or controlled) of 9 summarised | 23 human (19 randomized or controlled) of 27 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 9 mg, 15 mg | 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Semaglutide: trial and label
In STEP 1, semaglutide 2.4 mg produced a mean weight change of -14.9% against -2.4% on placebo at week 68.[19]
The Wegovy label carries a boxed warning: semaglutide causes thyroid C-cell tumours in rodents, and the human relevance is unknown.[21]
It also notes Wegovy delays gastric emptying.[21]
Sermorelin in children and older men
In a one-year trial in GH-deficient children, mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr after 6 months of sermorelin therapy.[18]
In older men on nightly GHRH injections, weight, DEXA measures of muscle and fat, and lipids did not change.[9]
Semaglutide discontinuations
In the STEP 1 trial more people stopped semaglutide than placebo because of gastrointestinal events: 59 [4.5%] vs. 5 [0.8%].[19]
Together
The sermorelin with semaglutide search returned 0 PubMed records.
Calculated from pubmed query (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab]) AND (sermorelin[tiab] OR Geref[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key semaglutide__sermorelin); no arithmetic applied.
The two differ in availability: semaglutide is FDA approved while sermorelin's only Drugs@FDA record is discontinued.[22]
Common questions
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 6Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 7Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 8Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 9Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 14Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 15Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 16Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 17PubMed search: (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 19Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 20PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 21WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 22Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.